Haleon plc: Completion of off-market purchase and Total Voting Rights and Capital

3 October 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that it has completed the off-market purchase of 60,526,315 ordinary shares of £0.01 each, repurchased from Pfizer Inc. ("Pfizer") for an aggregate purchase price of £230 million. 

The off-market purchase includes (i) 30,161,278 ordinary shares which Haleon has cancelled and (ii) 30,365,037 ordinary shares which will be held as treasury shares.

As at 3 October 2024, the total number of ordinary shares issued by Haleon is 9,083,725,919, of which 30,365,037 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 9,053,360,882 and this figure may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. 

Amanda Mellor 

Company Secretary 

Enquiries

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information please visit www.haleon.com